GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » Asset Turnover

Alere (ALRPRB.PFD) Asset Turnover : 0.10 (As of Jun. 2017)


View and export this data going back to 2008. Start your Free Trial

What is Alere Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Alere's Revenue for the three months ended in Jun. 2017 was $557.67 Mil. Alere's Total Assets for the quarter that ended in Jun. 2017 was $5,615.35 Mil. Therefore, Alere's Asset Turnover for the quarter that ended in Jun. 2017 was 0.10.

Asset Turnover is linked to ROE % through Du Pont Formula. Alere's annualized ROE % for the quarter that ended in Jun. 2017 was -20.82%. It is also linked to ROA % through Du Pont Formula. Alere's annualized ROA % for the quarter that ended in Jun. 2017 was -6.63%.


Alere Asset Turnover Historical Data

The historical data trend for Alere's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alere Asset Turnover Chart

Alere Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.37 0.38 0.39 0.41

Alere Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.10 0.11 0.10 0.10

Competitive Comparison of Alere's Asset Turnover

For the Diagnostics & Research subindustry, Alere's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alere's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Alere's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Alere's Asset Turnover falls into.



Alere Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Alere's Asset Turnover for the fiscal year that ended in Dec. 2016 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2016 )/( (Total Assets (A: Dec. 2015 )+Total Assets (A: Dec. 2016 ))/ count )
=2376.335/( (5918.16+5648.279)/ 2 )
=2376.335/5783.2195
=0.41

Alere's Asset Turnover for the quarter that ended in Jun. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2017 )/( (Total Assets (Q: Mar. 2017 )+Total Assets (Q: Jun. 2017 ))/ count )
=557.672/( (5673.869+5556.835)/ 2 )
=557.672/5615.352
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Alere  (NYSE:ALRPRB.PFD) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Alere's annulized ROE % for the quarter that ended in Jun. 2017 is

ROE %**(Q: Jun. 2017 )
=Net Income/Total Stockholders Equity
=-372.272/1788.1155
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-372.272 / 2230.688)*(2230.688 / 5615.352)*(5615.352/ 1788.1155)
=Net Margin %*Asset Turnover*Equity Multiplier
=-16.69 %*0.3972*3.1404
=ROA %*Equity Multiplier
=-6.63 %*3.1404
=-20.82 %

Note: The Net Income data used here is four times the quarterly (Jun. 2017) net income data. The Revenue data used here is four times the quarterly (Jun. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Alere's annulized ROA % for the quarter that ended in Jun. 2017 is

ROA %(Q: Jun. 2017 )
=Net Income/Total Assets
=-372.272/5615.352
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-372.272 / 2230.688)*(2230.688 / 5615.352)
=Net Margin %*Asset Turnover
=-16.69 %*0.3972
=-6.63 %

Note: The Net Income data used here is four times the quarterly (Jun. 2017) net income data. The Revenue data used here is four times the quarterly (Jun. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Alere Asset Turnover Related Terms

Thank you for viewing the detailed overview of Alere's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Alere (ALRPRB.PFD) Business Description

Traded in Other Exchanges
N/A
Address
Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.
Executives
John Bridgen officer: Sr VP, Business Development 51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri officer: Senior VP, Global R&D 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell officer: Senior VP, Global Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers director C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant officer: VP, Controller, CAO 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan officer: SVP, Global Quality & Reg. 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp officer: Global Pres., Cardiometabolic 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani officer: Global Pres., Toxicology 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt director 51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon officer: SVP, Global Human Resources 4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy director C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453

Alere (ALRPRB.PFD) Headlines

From GuruFocus

5 Resilient Biotech Stocks to Buy for 2012

By Vatalyst.com Vatalyst.com 02-28-2012

The Transformation in Alere

By Bavneet Singh Nagpal bavinagpal 05-22-2015

Alere Reports 2nd Quarter

By Alberto Abaterusso Alberto Abaterusso 08-04-2017

Mario Gabelli's Asset Fund Q3 2014 Commentary

By Vera Yuan Vera Yuan 11-21-2014

Prem Watsa Trims IBM, Berkshire Hathaway

By Tiziano Frateschi Tiziano Frateschi 02-26-2018

Diamond Hill Capital Comments on Alere Inc

By Vera Yuan Vera Yuan 10-17-2014

Diamond Hill Capital Comments on Alere Inc

By Vera Yuan Vera Yuan 03-17-2015

Alere Reaches Settlement With SEC

By Alberto Abaterusso Alberto Abaterusso 09-29-2017